What is SciFluor Life Sciences?
SciFluor Life Sciences operates at the intersection of medicinal chemistry and clinical pharmacology, focusing on the development of proprietary drugs targeting well-understood biological pathways. The company's core competency lies in its ability to optimize therapeutic candidates for diseases with significant medical burdens, including fibrotic conditions and back-of-the-eye disorders. Its lead clinical candidate, SF0166, represents a flagship innovation in ophthalmology, utilizing a novel eye drop delivery mechanism to treat ocular diseases that have historically required invasive interventions. By prioritizing high-impact therapeutic areas, SciFluor maintains a focused market position that balances scientific innovation with clear clinical utility.
How much funding has SciFluor Life Sciences raised?
SciFluor Life Sciences has raised a total of $44.6M across 2 funding rounds:
Series A
$30M
Series B
$14.6M
Series A (2015): $30M with participation from Allied Minds and Woodford Investment Management
Series B (2021): $14.6M, investors not publicly disclosed
Key Investors in SciFluor Life Sciences
Allied Minds
Allied Minds is an intellectual property commercialization firm that focuses on transforming early-stage technologies from research institutions into viable commercial enterprises.
Woodford Investment Management
Woodford Investment Management is a UK-based financial services firm that historically managed diverse investment portfolios, including significant stakes in patient capital and life sciences ventures.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for SciFluor Life Sciences?
With the recent infusion of capital, SciFluor Life Sciences is well-positioned to scale its clinical trial operations and expand its drug discovery pipeline. The strategic focus will likely remain on the advancement of SF0166 through late-stage clinical development, while simultaneously exploring new applications for its proprietary platform in neuroscience and fibrotic disease management. As the company matures, the emphasis will shift toward regulatory milestones and potential commercialization partnerships, ensuring that its pipeline of therapeutic candidates can effectively reach patient populations. The firm's ability to maintain its intellectual property edge will be paramount as it navigates the complexities of the global pharmaceutical landscape.
See full SciFluor Life Sciences company page
